Market Place
Sourcing Support
Amneal`s Generics Doxycycline Hyclate Receives Approval in US
04 Dec 2024 //
FDA
Amneal to Participate at Upcoming Investor Conferences
04 Dec 2024 //
BUSINESSWIRE
Amneal Wins FDA Nod for GLP-1 Generic
22 Nov 2024 //
BIOSPACE
Amneal Resubmits DHE Autoinjector NDA; FDA Approves Exenatide
22 Nov 2024 //
BUSINESSWIRE
Amneal Reports Q3 2024 Financial Results
08 Nov 2024 //
BUSINESSWIRE
Amneal Receives FDA Approval For Pyridostigmine Bromide Tablets
21 Oct 2024 //
BUSINESSWIRE
Amneal Expands In India With Two New Manufacturing Facilities
08 Oct 2024 //
EXPRESSPHARMA
Amneal to Report Third Quarter 2024 Results on November 8, 2024
08 Oct 2024 //
BUSINESSWIRE
Amneal And Metsera Partner On Next-Gen Obesity Medicines
01 Oct 2024 //
BUSINESSWIRE
Amneal Launches CREXONT For Parkinson`s Disease Treatment
23 Sep 2024 //
BUSINESSWIRE
Amneal asks court to block Colorado`s free allergy pen program
23 Sep 2024 //
REUTERS
Amneal and Shilpa Announce FDA Approval Of BORUZU, Ready-to-Use
05 Sep 2024 //
BUSINESSWIRE
Amneal Gets FDA Approval For Propofol Injectable Emulsion Single Dose Vials
20 Aug 2024 //
BUSINESSWIRE
Amneal Reports Second Quarter 2024 Financial Results
09 Aug 2024 //
BUSINESSWIRE
Amneal Receives FDA Approval For CREXONT To Treat Parkinson`s Disease
07 Aug 2024 //
BUSINESSWIRE
Amneal Clinches Approval For Extended-Release Parkinson`s Med
07 Aug 2024 //
FIERCE PHARMA
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
29 Jul 2024 //
BUSINESSWIRE
Amneal to Report Second Quarter 2024 Results on August 9, 2024
11 Jul 2024 //
BUSINESSWIRE
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
09 Jul 2024 //
BUSINESSWIRE
Amneal`s Generic Calcium Chloride Receives Approval in US
09 Jul 2024 //
FDA
Amneal Adds Omalizumab Biosimilar To Portfolio, Now Eight Products
01 Jul 2024 //
BUSINESSWIRE
Amneal Releases 2023 Environmental, Social and Governance Report
28 Jun 2024 //
BUSINESSWIRE
Amneal’s Early Win Delists Five Teva Orange Book Inhaler Patents
11 Jun 2024 //
BLOOMBERGLAW
Alembic`s Generic Venlafaxine Hydrochloride Receives Approval in US
06 Jun 2024 //
FDA
Amneal`s Generic Azelastine Hydrochloride Receives Approval in US
05 Jun 2024 //
FDA
Amneal: Expands Injectables Portfolio To Over 40 Products
05 Jun 2024 //
BUSINESSWIRE
Amneal Launches OTC Naloxone In US Retail, California
22 May 2024 //
BUSINESSWIRE
Amneal to Participate at Upcoming Investor Conference
22 May 2024 //
BUSINESSWIRE
Amneal Pharms LLC’s Generic Nimodipine Receives Tentative Approval In US
14 May 2024 //
FDA
Drugmaker Amneal agrees to $270 million U.S. opioid settlement
04 May 2024 //
REUTERS
Amneal Reports First Quarter 2024 Financial Results
03 May 2024 //
BUSINESSWIRE
Amneal`s OTC Naloxone Nasal Spray Approved
24 Apr 2024 //
BUSINESSWIRE
Enforcement Report - Week of April 24, 2024
24 Apr 2024 //
FDA
Amneal Pharm Generic Naloxone Hydrochloride Receives Approval in the U.S.
23 Apr 2024 //
FDA
Amneal appoints Sandeep Raktate as President -Operations, India & Ireland
19 Apr 2024 //
EXPRESSPHARMA
Shilpa Medicare launches Pemetrexed injection
19 Apr 2024 //
INDINPHARMAPOST
Amneal Launches PEMRYDI RTU® Oncology Injectable Ready-To-Use
16 Apr 2024 //
BUSINESSWIRE
Amneal to Report First Quarter 2024 Results on May 3, 2024
10 Apr 2024 //
BUSINESSWIRE
Enforcement Report - Week of April 3, 2024
03 Apr 2024 //
FDA
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024
28 Mar 2024 //
BUSINESSWIRE
Amneal pulls 4 lots of potentially overfilled antibiotic bottles
28 Mar 2024 //
FIERCE PHARMA
Amneal Pharm Generic Lacosamide Receives Approval in the U.S.
27 Mar 2024 //
FDA
Amneal gains FDA greenlight to develop Ciprodex generic for ear infections
26 Mar 2024 //
PHARMACEUTICAL TECHNOLOGY
Amneal Receives FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension
25 Mar 2024 //
BUSINESSWIRE
Enforcement Report - Week of February 28, 2024
28 Feb 2024 //
FDA
Amneal Enters into European Licensing Agreement with Zambon Biotech for IPX203
27 Feb 2024 //
PRESS RELEASE
Enforcement Report - Week of February 14, 2024
14 Feb 2024 //
FDA
Amneal to Participate at Upcoming Investor Conference
13 Feb 2024 //
BUSINESSWIRE
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application
08 Feb 2024 //
GLOBENEWSWIRE
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024
31 Jan 2024 //
BUSINESSWIRE
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension
10 Jan 2024 //
BUSINESSWIRE
Amneal`s Generic Fluorometholone Receives Approval in the U.S.
09 Jan 2024 //
FDA
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023
04 Jan 2024 //
BUSINESSWIRE
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
BUSINESSWIRE
GSK, Amneal and Kaleo walk back patents after FTC`s challenge
21 Dec 2023 //
FIERCE PHARMA
Amneal Announces Move to Nasdaq
15 Dec 2023 //
BUSINESSWIRE
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
07 Dec 2023 //
BUSINESSWIRE
Amneal Expands Portfolio with Addition of Icosapent Ethyl Acid Soft Gel Capsules
01 Dec 2023 //
BUSINESSWIRE
Amneal Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
BUSINESSWIRE
